Skip to main content
Man with glasses in front of microscope.

Cardiac Rhythm Management

Our focus

Groundbreaking technologies that monitor, support diagnosis, and treat irregular heart rhythms, heart failure and sudden cardiac arrest.

Mike's story

We are collaborating with healthcare professionals to help improve outcomes, enhance patients' lives, and reduce costs with the most advanced and least invasive cardiac rhythm management monitoring and therapeutic technologies available.

Delivering meaningful innovation

Improving patient management through personalized care.

Our MR-conditional Resonate™ family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems feature the HeartLogic™ Heart Failure Diagnostic to help physicians improve heart failure (HF) management. SmartCRT™ Technology incorporated in the devices helps physicians determine where, when and how to pace, while industry-leading device longevity is provided through EnduraLife™ Battery Technology.

Pioneering progressive ICD therapy.

The EMBLEM™ MRI S-ICD System is the only MR-conditional subcutaneous implantable defibrillator (S-ICD) that provides protection for patients at risk for sudden cardiac death. Because it provides protection without touching the heart or substernal space, the device eliminates many of the complications associated with transvenous leads placed in those locations. The EMBLEM S-ICD System is placed entirely outside the rib cage and just beneath the skin of a patient, and avoids complications associated with more invasive leads.

For the rhythms of life.

Boston Scientific Cardiac Diagnostics, a wholly owned subsidiary of Boston Scientific, provides mobile health solutions and remote monitoring services that connect physicians with patients threatened by cardiac arrhythmias. The BodyGuardian™ family of remote, wearable cardiac monitors is led by sophisticated ambulatory cardiac monitoring technology, and along with the PatientCare platform offers near real-time analysis of ambulatory echocardiogram data designed to support clinical diagnosis and outcomes. The BeatLogic technology applies artificial intelligence to support clinician decision making.

check icon

S-ICD: First and only subcutaneous implantable defibrillator.

check icon

Nearly 2x the usable battery capacity of Medtronic ICDs.¹

check icon

HeartLogic: 70% sensitivity in detecting heart failure events several weeks in advance.²

Conditions we treat

  • Heart Rhythm Disorders
  • Sudden Cardiac Arrest
  • Heart Failure


An estimated 6.2M American adults were diagnosed with heart failure between 2013 and 2016.3


More than 356K people experience out-of-hospital cardiac arrests annually in the U.S., and nearly 90% of those incidents are fatal.4


In 2016, approximately 280K emergency visits in the U.S. were for tachycardias and another 115K were for bradycardias.5


An estimated 38M people globally have atrial fibrillation (Afib).5


Approximately 13% of the estimated 5.3 million cases of Afib in the U.S. are undiagnosed.6

Solutions offered

  • Pacemakers
  • Implantable cardioverter defibrillators (ICDs)
  • Subcutaneous implantable defibrillator (S-ICD)
  • Cardiac resynchronization therapy defibrillators (CRT-Ds)
  • Remote monitoring systems
  • Pacing and ICD leads
  • Insertable cardiac monitors (ICMs)
  • Wearable monitors and services (through Boston Scientific Cardiac Diagnostics)

Product spotlights


  1. Ellis C, Markus T, Dickerman D, Orton J, Hassan S, Good E, Okabe T, Greenspon A. Ampere Hour as a Predictor of CRT ICD Pulse Generator Longevity: A Multi-Center Study. Presented at HFSA 2014. Ampere Hour (Ah) as a Predictor of CRT ICD Pulse Generator Battery Longevity Study. The five major institutions performing the study include, at Vanderbilt University, Eastside Cardiovascular Medicine, University of Michigan, Thomas Jefferson University, Robert Wood Johnson University Hospital, Cooper Health System and North Ohio Research. Boston Scientific = 266 patients, Medtronic = 542 patients, St. Jude Medical = 149 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.
  2. Boehmer, JP, Hariharan R, Devecchi FG, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices; Results from the MultiSENSE study. JACC Heart Fail. 2017 Mar:5(3)216-25.
  3. NHANES data. Source: Heart Disease and Stroke Statistics – 2019 Update.
  4. According to the Healthcare Cost and Utilization Project (HCUP) data. Source:
  5. Lippi G, Sanchis-Gomar F., et al. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021; Feb 16:217-221.
  6. Turakhia MP, Shafrin J, Bognar K, et al. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS One. 2018;13(4):e0195088. Published 2018 Apr 12. doi:10.1371/journal.pone.019508814